You are here

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Phase 1
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests and
other study procedures

- Healthy female subjects and/or male subjects who, at the time of screening, are
between the ages of 18 and 55 years, inclusive

- Female subjects with child-bearing potential must not be intending to become pregnant,
currently pregnant, or lactating. Conditions apply: negative pregnancy test, effective
method of contraception

- Non-childbearing potential must meet at least 1 of the following criteria: documented
hysterectomy and/or bilateral oophorectomy, ovarian failure, achieved postmenopausal
status confirmed with FSH

- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, GI, CV, hepatic, psych, neurological, or allergic disease (including drug
allergies, but excluding seasonal)

- Evidence or history of clinically significant dermatological condition (eg, contact
dermatitis or psoriasis) or visible rash present during physical examination

- Subjects, who according to the product label for midazolam, would be at increased risk
if dosed with midazolam

- Self-reported history or risk factors for QT prolongation or torsades de pointes,
congenital deafness, family history of sudden death, and family history of long QT
syndrome

- Any condition possibly affecting drug absorption (eg, gastrectomy)

- A positive urine drug test

- History of regular alcohol consumption exceeding 14 for female or 21 for male
drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard
liquor) within 6 months of screening

- Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceding the first dose of investigational product
(whichever is longer)

- Following at least 5 minutes of supine rest, screening supine systolic BP >=140 mm Hg, or screening supine diastolic BP =90 mm Hg. Any criteria
met, BP should be repeated

- Screening supine 12-lead ECG demonstrating: QTcF >450 msec or QRS interval >120 msec.
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated

- AST/SGOT or ALT/SGPT >=1.5 × ULN. Total bilirubin level >1× ULN; subjects with a hx of
Gilbert's syndrome must have direct bilirubin elevated liver function tests (LFTs)

- History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.
Positive QuantiFERON® - TB Gold test

- Any history of chronic infections, any history of recurrent infections, any history of
latent infections, or any acute infection within 2 weeks of baseline

- History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent
localized dermatomal herpes zoster

- History of sensitivity to heparin or heparin-induced thrombocytopenia

- Pregnant or breastfeeding female; fertile male and WOCBP unwilling to use a highly
effective method of contraception through study duration and for at least 28 days
after the last dose

- Use of medications and dietary supplements within 7 days or 5 half-lives prior to
first dose, acetaminophen/paracetamol hormonal methods of contraception

- Use of tobacco- or nicotine- containing products in excess of the equivalent of 5
cigarettes per day

- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 60 days prior to first dose of investigational product

- History of hypersensitivity to midazolam or any other bezodiazapine

- History of HIV, hepatitis B or C; positive testing for HIV, HepBsAg, HepBcAb or HCVAb.
As an exception, a positive HepBsAb as a result of subject vaccination is permissible

- Unwilling or unable to comply with the criteria in the Lifestyle Requirements section
of this protocol

- Investigator site staff members and their family members, site staff members otherwise
supervised by the investigator, or subjects who are Pfizer employees, including their
family members

- Other medical or psych condition including active suicidal ideation/ behavior or lab
abnormality that the investigator deems inappropriate for this study or may interfere
with study results

- Have any malignancies or have a history of malignancies with the exception of
adequately treated or excised non-metastatic basal cell or squamous cell cancer of the
skin, or cervical carcinoma in situ

- Subjects at significant risk of suicidal or violent behavior

NCT03647670
Pfizer
Completed
A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now